Holen Sie sich die Stockscreener-App
1.49
7.97%
0.11
Handel nachbörslich:
1.42
-0.07
-4.70%
Schlusskurs vom Vortag:
$1.38
Offen:
$1.44
24-Stunden-Volumen:
202.74K
Relative Volume:
1.10
Marktkapitalisierung:
$97.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.08M
KGV:
-0.6906
EPS:
-2.1574
Netto-Cashflow:
$-72.06M
1W Leistung:
-1.32%
1M Leistung:
-8.02%
6M Leistung:
+60.94%
1J Leistung:
+26.27%
1-Tages-Spanne:
$1.42
$1.50
1-Wochen-Bereich:
$1.30
$1.55
52-Wochen-Spanne:
$0.66
$1.73
Io Biotech Inc Stock (IOBT) Company Profile
Firmenname
Io Biotech Inc
Sektor
Branche
Telefon
(457) 070-2980
Adresse
OLE MAALOES VEH 3, COPENHAGEN
Vergleichen Sie IOBT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOBT
Io Biotech Inc
|
1.49 | 97.50M | 0 | -86.08M | -72.06M | -2.1574 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Io Biotech Inc Aktie (IOBT) Neueste Nachrichten
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Down 35.0% in May - Defense World
IO Biotech Regains Nasdaq Compliance with Stock Price - MSN
Wall Street Zen Upgrades IO Biotech (NASDAQ:IOBT) to “Sell” - Defense World
NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Companies and 10+ Therapies | DelveInsight - The Globe and Mail
5 "Best" Publicly Traded Synthetic Biology Companies - Securities.io
Metastatic Melanoma Pipeline Appears Robust With 20+ Key Pharma - openPR.com
IO Biotech reports annual meeting results By Investing.com - Investing.com Nigeria
IO Biotech reports annual meeting results - Investing.com India
IO Biotech Elects New Director at Annual Meeting - TipRanks
Citadel Advisors LLC Purchases Shares of 270,504 IO Biotech, Inc. (NASDAQ:IOBT) - Defense World
IO Biotech Regains Compliance With Nasdaq Listing Rules - marketscreener.com
io biotech regains nasdaq compliance after bid price recovery By Investing.com - Investing.com India
io biotech regains nasdaq compliance after bid price recovery - Investing.com
Director Heidi Hunter Acquires 15,000 Shares of IO Biotech Inc (IOBT) - GuruFocus
Stocks in play: Corus Entertainment - The Globe and Mail
Io biotech director Heidi Hunter purchases $20,884 in common stock By Investing.com - Investing.com South Africa
Io biotech director Heidi Hunter purchases $20,884 in common stock - Investing.com Australia
5 Best Microbiome Companies (June 2025) - Securities.io
Here Are My Top 3 High-Yield Pipeline Stocks to Buy Now - The Globe and Mail
Pembina Pipeline Corporation Announces Redemption of Series 19 Preferred Shares - The Globe and Mail
3 Internet Software Stocks to Buy From a Prospering Industry - The Globe and Mail
Cancer Vaccines Market Sees Boost from UK's New Injection and Korea's Cell Conversion Research - openPR.com
Dividend 15 Split Corp. II Announces TSX Acceptance of Normal Course Issuer Bid - The Globe and Mail
IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy? - sharewise
Beyond Lithium Completes Acquisition of Rare One Project in Southeastern British Columbia - The Globe and Mail
Targeting solid tumors two ways with one cancer vaccine - drugdiscoverynews.com
Prediction: This Will Be the First Mega Technology Company to Split Its Stock in 2025 (and It Isn't Tesla) - The Globe and Mail
Io Biotech Inc Files For Resale Of Up To 5.6 Million Shares Of Common Stock By The Selling StockholdersSEC Filing - marketscreener.com
IOBT Investors: Understanding Stockholder Sales Impact | IOBT St - GuruFocus
2 "Magnificent Seven" Stocks Billionaires Are Buying - The Globe and Mail
Elliott Waves: Dollar Index Can Be Targeting New Lows - The Globe and Mail
IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference - The Manila Times
Cancer Vaccine Developer IO Biotech Headlines Two Major Healthcare Conferences This Summer - Stock Titan
Is NIO Stock Set for a Comeback? Fundamentals Say Yes - The Globe and Mail
Q2 Earnings Forecast for IO Biotech Issued By HC Wainwright - Defense World
Sustainable Success Stories: 2 U.S. Companies With a Legacy of Growth - The Globe and Mail
Why Alphabet Stock Ticked Higher Today - The Globe and Mail
IO Biotech Advances Cancer Vaccine Trials in Q1 2025 - TipRanks
IO Biotech price target raised to $14 from $12 at H.C. Wainwright - Yahoo Finance
Why American Eagle Stock Plummeted After Earnings - The Globe and Mail
IO Biotech, Inc. SEC 10-Q Report - TradingView
IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
‘We’re Delivering Real Progress Toward Profitability:’ Is Plug Power Stock a Buy, Sell, or Hold After Earnings? - The Globe and Mail
IO Biotech (IOBT) Projected to Post Quarterly Earnings on Tuesday - Defense World
4 No-Brainer Stocks to Buy Right Now - The Globe and Mail
Renaissance Technologies LLC Raises Stake in IO Biotech, Inc. (NASDAQ:IOBT) - Defense World
“Horrible Things Done to Slack,” says Salesforce (NYSE:CRM) CEO Benioff about Microsoft - The Globe and Mail
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of IO Biotech, Inc. (NASDAQ: IOBT) and Encourages IOBT Shareholders to Contact the Firm - ACCESS Newswire
Finanzdaten der Io Biotech Inc-Aktie (IOBT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Io Biotech Inc-Aktie (IOBT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ahmad Qasim Iftikhar | Chief Medical Officer |
Dec 23 '24 |
Buy |
0.85 |
31,350 |
26,553 |
31,350 |
| Zocca Mai-Britt | Chief Executive Officer |
Dec 23 '24 |
Buy |
0.81 |
12,500 |
10,120 |
49,891 |
| Sullivan Amy | Chief Financial Officer |
Dec 23 '24 |
Buy |
0.83 |
10,250 |
8,483 |
84,632 |
| Smith Devin Whittemore | General Counsel |
Dec 23 '24 |
Buy |
0.81 |
12,000 |
9,720 |
16,938 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):